Tam Fry: key facts
- Kind of voice
- Sector leader
- Role
- chair of the National Obesity Forum
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 27 Aug 2026
“Orforglipron [could prove] itself as the treatment of choice for the very obese diabetic. Its real bonus is in its straightforward use. When it is finally released, its availability must be more strictly controlled than semaglutide to avoid similar life-threatening usage.”
Where Tam Fry has been quoted
- New GLP-1 pill helps patients lose up to 8% of body weight, trial showstheguardian.com · 27 Aug 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.